Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — FY2022 Earnings Presentation
23 slides from Aft Pharmaceuticals's earnings presentation, May 2022
Slide 1: Investor Presentation May 2022
INVESTOR PRESENTATION MAY 2022
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of the performance of AFT for the financial year ended 31 March 2022. It is not prepared for any other purpose and must not be provided to any person other than the intended rec
Slide 3: AFT is Expanding Globally From a Strong and Growing Australasian Core
AFT is Expanding Globally From a Strong and Growing Australasian Core AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 3
Slide 4: FY22 Highlights: Building on a Strong Record of Growth
FY22 Highlights: Building on a Strong Record of Growth • Annual operating revenue up 15.2% to $130.3 million from $113.1 million with all regions posting double digit growth, underpinned by AFT’s unique IP. • Operating profit $20.4 million up from $10.7 million with stronger second half as anticipat
Slide 5: Australia: New Product Launches Drive Growth
Australia: New Product Launches Drive Growth • Australian sales up 12.3% to $76.7 million from $68.3 million – 59% of group operating revenue across 70 products. • Double digit growth across all channels despite Covid-19 restrictions. • Revenue growth assisted by new launches (including deferred). A
Slide 6: New Zealand: Strong Growth as Country Recovers From Covid
New Zealand: Strong Growth as Country Recovers From Covid • New Zealand sales up 15.1% to $35.1 million from $30.5 million – 27% of group operating revenue across 130 products. • Revenue growth assisted by an increase in over-the-counter (OTC) sales as Covid restrictions eased as well as launches of
Slide 7: Asia: Sales Lifted by Hospital Channel Growth
Asia: Sales Lifted by Hospital Channel Growth • Sales in Asia up 24.7% to $5.5 million from $4.4 million – representing 4% of group operating revenue. • Hospital and prescription channels grew 32% due primarily to strong anti-bacterial sales. • OTC channel flat with growth in sales in Malaysia offse
Slide 8: International Maxigesic Roll Out Continues to Drive Revenue
International Maxigesic Roll Out Continues to Drive Revenue ROW Revenue Countries where Maxigesic is sold and ordered $14.0 100 90 CAGR 38.1% 90 $12.0 80 $10.0 70 63 $NZ Million 60 Countries $8.0 50 46 43 $6.0 40 28 $4.0 30 20 20 $2.0 7 9 10 2 3 4 $- 0 FY2018 FY2019 FY2020 FY2021 FY 2022 FY2014 FY20
Slide 9: Maxigesic Global Update
Maxigesic Global Update A US$59 billion market1 1 www.ex pertmark etres earc h.c om/reports /anal ges i c s-mark et 9
Slide 10: Investing in a Strong Research and Development Pipeline
Investing in a Strong Research and Development Pipeline NasoSURF PROJECT KW Research and development Ultrasonic nasal mesh nebuliser used for Gastrointestinal medicine $14.0 the intranasal delivery of medication and • Developing two formulations $12.0 treatment of sinus conditions and AFT IP positio
Slide 11: Building the Maxigesic Addressable Market With New Dose Forms
Building the Maxigesic Addressable Market With New Dose Forms • Estimated total analgesic Maxigesic® family growth Patent Expiry market size US$5.9 billion1 Maxigesic® DRY STICK SACHET 2036 • Maxigesic tablets are patent protected out to 2025-2028, Maxigesic ® COLD & FLU 2025, 2042 beyond which the
Slide 12: Solid Operating Profit in a Challenging Year
Solid Operating Profit in a Challenging Year Revenue Revenue NZ$'000's year ended 31 March 2022 % 2021 % • Delivered 15% Revenue Revenue 130,314 113,105 growth with margins benefiting Gross profit 61,775 47.4% 48,741 43.1% from US licensing income Operating expenses and other income (41,386) 31.8% (
Slide 13: Cash Flow: AFT Remains Well Funded as Debt Reduction Continues
Cash Flow: AFT Remains Well Funded as Debt Reduction Continues NZ$'000’s Year ended 31 March 2022 2021 • Operating cash flow increases Net cash from operating activities 14,152 750 as costs grow at a slower rate Net cash used in investing activities (5,585) (6,231) than revenue. Net cash used/(gener
Slide 14: Balance Sheet: Inventory Levels Elevated to Provide Buffer
Balance Sheet: Inventory Levels Elevated to Provide Buffer NZ$'000’s Year ended 31 March 2022 2021 • Anticipated elevated inventory during Current assets 69,602 64,693 FY23 to protect against supply Cash 7,940 3,209 disruptions. This approach has Non current assets 44,218 37,230 proved valuable. Tot
Slide 15: Dividend Policy: A Statement of Confidence in Our Future
Dividend Policy: A Statement of Confidence in Our Future • The Board expects the company to continue to grow underpinned by a strong defensible and growing core business in Australasia and a growing international business built on our unique IP. • On the basis of these strengths, the Board intends t
Slide 16: ESG Focusing on What Matters
ESG Focusing on What Matters Our Mission: Working to Improve Your Health AFT is committed to enhancing the health and wellbeing of people and communities in the markets we serve and operating a sustainable business. AFT PHARMACEUTICALS WORKING TO IMPROVE YOUR HEALTH 16
Slide 17: Outlook
Outlook • Continue to see considerable opportunities for growth and we have significantly increased both our in-licensing and product and R&D pipeline activities • Expect to see a return to a more normal trading environment as COVID-19 becomes endemic. • Focus areas for the new financial year on opp
Slide 18: Questions
QUESTIONS /
Slide 19: Appendix 1: Australasian Product Portfolio
Appendix 1: Australasian Product Portfolio AFT has the #1 selling product (Maxigesic) in the Australian para-ibu1 combo pain relief. AFT’s portfolio includes a combination of 125 proprietary, branded and generic products which address the following therapeutic areas: Maxigesic, ParaOsteo, ZoRub OA/H
Slide 20: Appendix 2: AFT Asian Product Portfolio
Appendix 2: AFT Asian Product Portfolio AFT’s Asia portfolio includes a range of proprietary, branded and generic products which address the following therapeutic areas: Pain Maxigesic Ferro-sachets, Lipo VitC, Lipo VitD and Medicated Vitamins expanding pipeline – T Mall Dermatology Crystawash Exten
Slide 21: Appendix 3: AFT Global Product Portfolio
Appendix 3: AFT Global Product Portfolio AFT is building the global presence of its proprietary and patented products through its network of licensees and distributors. It continues the development of its portfolio of repurposed medicines: Maxigesic, Pascomer, NasoSURF, Crystawash Extend and Crystad
Slide 22: Appendix 4: History of AFT Pharmaceuticals
Appendix 4: History of AFT Pharmaceuticals AFT was founded 23 years ago by Dr Hartley and Marree Atkinson. Since then AFT has remained an Atkinson-family controlled business and has grown organically into Australia and internationally The 2015 IPO raised funds to pursue a more aggressive (and loss-m
Slide 23: www.aftpharm.com
Fs i www.aftpharm.com / AFIT pharmaceuticals Working to improve your health